492 completed, 124 terminated, 88 recruiting, 51 unknown. 392 Phase 2, 364 Phase 1, 70 Phase 3, 59 Not applicable, 5 Early Phase 1.
Follow this condition Literature Review of Lymphoma, B-Cell, Marginal Zone trials Research Report on Lymphoma, B-Cell, Marginal Zone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-12-16 | 2026-09-29 |
| Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Nodal Marginal Zone Lymphoma | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 138 | 2026-10-03 | 2026-10-13 |
| Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma Therapeutic Hydrocortisone, Cytarabine, Dexamethasone - Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 59 | 2026-09-25 | 2026-10-02 |
| Molecular and Cellular Characterization of MALT Lymphoma MALT Lymphoma | Not yet recruiting | International Extranodal Lymphoma Study Group (IELSG) | 400 | 2026-09-01 | 2026-06-22 | |
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Paolo Caimi, MD | 15 | 2026-09-01 | 2026-09-09 |
| A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas CART Infusion - Lymphoma Nonhodgkin, Marginal Zone B Cell Lymphoma | Phase 2 | Not yet recruiting | Kure Cells, INC | 105 | 2026-08-31 | 2026-07-20 |
| A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma Radiation (Very low dose), Radiation (Standard) - Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) | Phase 2 | Not yet recruiting | Ruijin Hospital | 140 | 2026-08-01 | 2026-07-15 |
| Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy Atrial Fibrillation (AF), Chronic Lymphocytic Leukemia | Not yet recruiting | Tina Baykaner | 500 | 2026-08-01 | 2026-07-17 | |
| Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors Connected home blood pressure monitoring with daily IPA supervision. - Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma ( FL) | Not applicable | Not yet recruiting | Centre Hospitalier de la côte Basque | 40 | 2026-07-01 | 2026-06-22 |
| Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma Rituximab, Observation - Marginal Zone Lymphoma(MZL) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 144 | 2026-07-01 | 2026-06-17 |
| A Study of ARC-02 in B-cell NHL ARC-02, Rituximab - B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Taiho Oncology, Inc. | 140 | 2026-06-22 | 2026-10-08 |
| A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) LY4152199 - IV - Lymphoma, Non-Hodgkin, B-cell Lymphoma | Phase 1 | Recruiting | Eli Lilly and Company | 215 | 2026-05-28 | 2026-10-08 |
| Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma Pomalidomide - Indolent Lymphoma, Follicular Lymphoma | Not yet recruiting | The First Affiliated Hospital of Soochow University | 30 | 2026-05-01 | 2026-05-27 | |
| Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma Orelabrutinib, Ultra-low-dose Radiation Therapy - MALT Lymphoma | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 60 | 2026-04-16 | 2026-05-11 |
| Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma MDX2003 - Lymphoma, Waldenström Macroglobulinemia (WM) | Phase 1 / Phase 2 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 180 | 2026-04-13 | 2026-05-04 |
| Cognitive Impairment in Patients Undergoing Cell- and Antibody-based Immunotherapies for Haematological Malignancies: The COGNITOX Study Neuropsychological tests and patient reported outcome - Malignant Lymphoma - Lymphoplasmacytic, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma | Not yet recruiting | Aarhus University Hospital | 225 | 2026-03-31 | 2026-04-30 | |
| Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma lisocabtagene maraleucel - Marginal Zone Lymphoma | Active not recruiting | Bristol-Myers Squibb | 300 | 2026-03-24 | 2026-08-20 | |
| Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) Venetoclax - Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma | Phase 2 | Active not recruiting | AbbVie | 14 | 2026-03-17 | 2026-09-09 |
| A Study of APG-3288 in Relapsed/Refractory Blood Cancers APG-3288 - Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL | Phase 1 | Recruiting | Ascentage Pharma Group Inc. | 180 | 2026-03-10 | 2026-10-15 |
| A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies MTM-H-001 Injection - Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Follicular | Not applicable | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 69 | 2026-03-01 | 2026-03-17 |
Showing 20 of 863. Sign in to see all of them.
Lymphoma, Follicular (720) · Leukemia, Lymphocytic, Chronic, B-Cell (628) · Lymphoma, Mantle-Cell (624) · Lymphoma, Large B-Cell, Diffuse (554) · Lymphoma, Non-Hodgkin (542) · Burkitt Lymphoma (458) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (425) · Lymphoma, Large-Cell, Immunoblastic (409) · Lymphoma (400) · Hodgkin Disease (343) · Waldenstrom Macroglobulinemia (343) · Lymphoma, T-Cell, Cutaneous (266) · Multiple Myeloma (252) · Mycosis Fungoides (235)
Hemic and Lymphatic Diseases (863) · Immunoproliferative Disorders (860) · Lymphatic Diseases (860) · Immune System Diseases (859) · Neoplasms by Histologic Type (859) · Lymphoproliferative Disorders (828) · Neoplasms (799) · Lymphoma, B-Cell (797) · Hematologic Diseases (682) · Pathologic Processes (647) · Pathological Conditions, Signs and Symptoms (647) · Disease Attributes (646) · Leukemia, Lymphoid (635) · Chronic Disease (630) · Leukemia, B-Cell (622)
Rituximab (163) · Cyclophosphamide (143) · fludarabine phosphate (89) · Peripheral Blood Stem Cell Transplantation (81) · Filgrastim (59) · Mycophenolic Acid (58) · Cyclosporine (53) · Whole-Body Irradiation (53) · Radiotherapy (52) · Lenalidomide (47) · Busulfan (45) · Tacrolimus (44) · Etoposide (43) · Antilymphocyte Serum (41) · Melphalan (37)
National Cancer Institute (NCI) (80) · Fred Hutchinson Cancer Center (56) · Memorial Sloan Kettering Cancer Center (28) · City of Hope Medical Center (25) · Masonic Cancer Center, University of Minnesota (24) · Mayo Clinic (24) · Case Comprehensive Cancer Center (19) · Roswell Park Cancer Institute (15) · Barbara Ann Karmanos Cancer Institute (13) · M.D. Anderson Cancer Center (13) · National Institutes of Health Clinical Center (CC) (13) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (13) · International Extranodal Lymphoma Study Group (IELSG) (12) · Jonsson Comprehensive Cancer Center (12) · Northwestern University (12)
United States (672) · Italy (61) · France (58) · China (53) · Germany (45) · United Kingdom (43) · Australia (36) · Spain (35) · Canada (32) · South Korea (32) · Switzerland (26) · Poland (24) · Belgium (20) · Israel (19) · Japan (19)
Ajay Gopal (7) · David Maloney (6) · Brenda Sandmaier (5) · Christos E. Emmanouilides, MD (5) · Emanuele Zucca, MD (5) · Julie M Vose, MD (5) · Philip L. McCarthy, MD (5) · Thomas E. Witzig, MD (5) · Jane N. Winter, MD (4) · Kami Maddocks, MD (4) · Robert Kreitman, MD (4) · Roger Strair, MD, PhD (4)
PMID 40550489, PMID 32499241, PMID 34398557, PMID 34515338, PMID 34780125, PMID 19949018, PMID 20028764, PMID 22002018, PMID 22337718, PMID 23065509, PMID 23233721, PMID 27879257, PMID 36375120, PMID 39007066, PMID 40472301, PMID 42411504, PMID 42541678, PMID 10552943, PMID 10764422, PMID 11410496, PMID 11756154, PMID 12171484, PMID 12525530, PMID 14508361, PMID 14630685, PMID 14767498, PMID 15013589, PMID 15107815, PMID 15459300, PMID 15570084, PMID 16061911, PMID 16135477, PMID 16148284, PMID 16174856, PMID 16731764, PMID 17020988, PMID 17119113, PMID 17242396, PMID 17312328, PMID 17397698, PMID 17889355, PMID 17910637, PMID 17943599, PMID 17947483, PMID 18226581, PMID 18293016, PMID 18327587, PMID 18463792, PMID 18470481, PMID 18509084
P30CA033572 (19), P30CA015083 (17), P30CA015704 (17), P30CA043703 (15), P30CA022453 (12), P30CA006973 (11), U01CA076576 (9), P30CA036727 (8), P30CA016058 (7), P30CA068485 (7), P30CA072720 (7), 2017 (6), 2023 (6), P01CA018029 (6), P30CA016672 (6)